-
Diminishment of HAART-related side effects.
One immediate effect of treatment breaks is that some side effects, such as fatigue and diarrhea, are reduced.
Viral load rebound.
As soon as anti-HIV medications leave the body, the virus begins to replicate. Viral load can shoot up sharply, often to pre-treatment levels.
Acute retroviral syndrome.
As viral load rises, it can trigger an immune response and flu-like symptoms, such as fever, swollen lymph nodes, and weakness. Some people experience this acute retroviral syndrome when they go off anti-HIV medications, just as many do when first infected with HIV.
CD4 cell decrease.
Typically, the number of CD4 cells begins to fall rapidly in the first weeks after a starting a treatment break, followed by a much more gradual loss over the long term. The CD4 count at the beginning of a treatment break often determines the duration of the interruption period.
HIV-associated conditions.
Falling CD4 cell count makes people taking treatment breaks more susceptible to opportunistic illnesses, such as herpes zoster (shingles), herpes simplex, and candidiasis (thrush), as well as other conditions, including thrombocytopenia (low blood platelet count).
Two Promising Integrase Inhibitors in the Pipeline
Possibly the most exciting news to come out of the 13th Conference on Retroviruses and Opportunistic Infections, held in Denver last February, concerned clinical trials of two experimental drugs in a new class: integrase inhibitors. If successful in further trials, integrase inhibitors could revitalize the treatment regimens of people living with multidrug-resistant HIV.
1. National Women and Girls HIV/AIDS Awareness Day 2. Black Church Week of Prayer for the Healing of AIDS 3. Updated Fact Sheets on African Americans and HIV 4. Tipsheet on Medicare Part D Coverage and People Living with HIV National Women and Girls HIV/AIDS Awareness Day: The first annual National Women and Girls HIV/AIDS Awareness Day. This day is set to raise awareness on the increasing impact of HIV/AIDS transmission on women and girls. In support of this event, the U.S. Department of Health and Human Services (DHHS) is hosting a National Women and Girls HIV/AIDS Awareness Day website that offers materials, including posters, flyers, and a fact sheet on women and girls and HIV, to assist in efforts to educate, motivate, and mobilize local communities in the fight against HIV/AIDS. The website also includes a list of events taking place across the country. Women and Girls HIV/AIDS Awareness Day is sponsored by the DHHS's Office on Women's Health. For more information go to: Black Church Week of Prayer for the Healing of AIDS: The Black Church Week of Prayer for the Healing of AIDS, , focuses on HIV/AIDS education and awareness highlighting the important role churches play in addressing the HIV/AIDS crisis. Each year, a growing number of Black congregations are supporting and caring for persons living with HIV/AIDS, developing AIDS prevention outreach programs, setting up HIV/AIDS ministries in the church and in the community, and establishing HIV testing facilities complete with staff and counselors knowledgeable about HIV/AIDS. This week of prayer calls upon Black faith communities worldwide to provide accessible services and resources for people who are infected with and affected by HIV/AIDS. The event is sponsored by the Balm in Gilead . For more information go to: http://www.balmingilead.org/programs/weekofprayer2006/default.asp Updated Fact Sheets on African Americans and HIV The Kaiser Family Foundation has released an updated fact sheet on African Americans and HIV/AIDS highlighting the epidemic's impact on African Americans and providing current data and trends over time. African Americans account for more AIDS diagnoses, people estimated to be living with AIDS, and HIV-related deaths than any other racial or ethnic group in the U.S. The percentage of AIDS diagnoses occurring among African Americans has risen from 25 percent in 1985 to approximately half in 2004. African-American women are also especially affected, accounting for two-thirds of new AIDS cases among women. The updated fact sheet is available at: http://www.kff.org/hivaids/6089.cfm Tipsheet on Medicare Part D Coverage and People Living with HIV As the transition to Medicare Part D coverage proceeds, this consumer-oriented tipsheet may be of value to you and your clients. The tipsheet provides information on Medicare drug plans, dual eligibility, frequently asked questions (FAQs) and resources on prescription drug coverage and ADAP. While we have mentioned this resource before, it recently was relocated on the Medicare website. To view the tipsheet go to: http://www.cms.hhs.gov/partnerships/downloads/AIDS.pdf ** Some good links ** http://maketheconnection.org/ ( cervical cancer) 
-
Diminishment of HAART-related side effects.
One immediate effect of treatment breaks is that some side effects, such as fatigue and diarrhea, are reduced.Viral load rebound.
As soon as anti-HIV medications leave the body, the virus begins to replicate. Viral load can shoot up sharply, often to pre-treatment levels.Acute retroviral syndrome.
As viral load rises, it can trigger an immune response and flu-like symptoms, such as fever, swollen lymph nodes, and weakness. Some people experience this acute retroviral syndrome when they go off anti-HIV medications, just as many do when first infected with HIV.CD4 cell decrease.
Typically, the number of CD4 cells begins to fall rapidly in the first weeks after a starting a treatment break, followed by a much more gradual loss over the long term. The CD4 count at the beginning of a treatment break often determines the duration of the interruption period.HIV-associated conditions.
Falling CD4 cell count makes people taking treatment breaks more susceptible to opportunistic illnesses, such as herpes zoster (shingles), herpes simplex, and candidiasis (thrush), as well as other conditions, including thrombocytopenia (low blood platelet count).Two Promising Integrase Inhibitors in the PipelinePossibly the most exciting news to come out of the 13th Conference on Retroviruses and Opportunistic Infections, held in Denver last February, concerned clinical trials of two experimental drugs in a new class: integrase inhibitors. If successful in further trials, integrase inhibitors could revitalize the treatment regimens of people living with multidrug-resistant HIV.